Structure base drug discovery company
Amura Holdings Ltd., Minerva Building, Babraham Research Campus, Babraham, CB22 3AT, U.K.
Home
Company
Technologies
Programmes
Osteoporosis
Autoimmunity
Malaria
Background (MAL)
Current status (MAL)
ß-lactamase inhibitors (BLIs)
Bone metastasis
Contact
Sitemap
Search
 
 
     
 

Background to Malaria programme

Falcipain-2 (FP-2) and falcipain-3 (FP-3) are cysteine peptidases produced by the human malaria parasite Plasmodium falciparum.  FP-2 and FP-3 catalyse the proteolysis of host proteins as a means of completing various stages of their life-cycles as well as acquiring nutrients.  FP-2 and FP-3 have been found to be essential for parasite growth and completion of the blood stage of their life-cycle.  Selective inhibition of FP-2 and/or FP-3 may provide a novel treatment for malaria.

Search MEROPS peptidase database: link to MEROPS here

 

 
     
Email: amura@amura.co.uk
Phone: +44(0)1223 839797 Fax: +44(0)1223 839898 Copyright © 2008 Amura Holdings Ltd.